Acupuncture & Electro-Therapeutics Research

New Study from AccessHope Affirms Cancer Subspecialist Reviews Improve Pancreatic Cancer Treatment Paths

Retrieved on: 
Tuesday, October 24, 2023
Neoplasm, Research, Cancer, City of Hope, Pancreas, Physician, Acupuncture & Electro-Therapeutics Research, Mortality, Prevalence, Dana–Farber Cancer Institute, City, Disease, LOS, Pancreatic cancer, Oncology, Therapy, Patient, Diagnosis, Pharmaceutical industry, Medical imaging, Hope

Pancreatic cancer is the third leading cause of cancer mortality in the U.S. but accounts for just 3% of cancer cases.

Key Points: 
  • Pancreatic cancer is the third leading cause of cancer mortality in the U.S. but accounts for just 3% of cancer cases.
  • Approximately 80-90% of patients with pancreatic cancer have unresectable tumors, meaning surgery is not a viable treatment option.
  • Determining the correct stage of disease at diagnosis and ensuring timely and coordinated multidisciplinary care is critical to attaining optimal outcomes for patients with pancreatic cancer.
  • The study on AccessHope's collaboration with NCI-Designated Comprehensive Cancer Centers evaluated data from 94 pancreatic cancer cases between August 2019 and December 2022.

FDA Approves LONSURF® (trifluridine/tipiracil) in Combination With Bevacizumab for Adult Patients With Metastatic Colorectal Cancer (mCRC)

Retrieved on: 
Wednesday, August 2, 2023
The New England Journal of Medicine, Bevacizumab, Acupuncture & Electro-Therapeutics Research, Progression-free survival, OS, Oncology, PFS, City, HIV disease progression rates, RAS, MD, Patient, Trifluridine/tipiracil, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Pharmaceutical industry

PRINCETON, N.J., Aug. 2, 2023 /PRNewswire/ -- Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved LONSURF® (trifluridine/tipiracil) as a single agent or in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

Key Points: 
  • PRINCETON, N.J., Aug. 2, 2023 /PRNewswire/ -- Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved LONSURF® (trifluridine/tipiracil) as a single agent or in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
  • "Notably, the use of LONSURF plus bevacizumab in these patients did not result in an increase in potentially intolerable side effects that might limit the utility of this combination."
  • On July 31, 2023, Servier, which conducted the SUNLIGHT trial with Taiho Oncology, received approval from the European Commission for LONSURF in combination with bevacizumab for the treatment of adult patients with mCRC who have received two prior anti-cancer treatment regimens, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.
  • The Marketing Authorization covers the 27 countries of the European Union as well as Iceland, Northern Ireland, Liechtenstein and Norway.

Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors

Retrieved on: 
Thursday, April 20, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Tissue, Human, City of Hope, Acupuncture & Electro-Therapeutics Research, TCE, Clinical trial, Head, Toxicity, Neck, City, Patient, EGFR, Colorectal cancer, Clinical research, Therapy, Safety, Renal cell carcinoma, Medical imaging, Hope

JANX008 is an epidermal growth factor receptor (EGFR) directed T cell engager (TCE) and is the second product candidate utilizing Janux’s TRACTr platform to be administered in humans.

Key Points: 
  • JANX008 is an epidermal growth factor receptor (EGFR) directed T cell engager (TCE) and is the second product candidate utilizing Janux’s TRACTr platform to be administered in humans.
  • “We are excited to initiate the clinical evaluation of our second product candidate from our TRACTr platform.
  • JANX008 is designed to achieve tumor-selective T-cell activation and tumor killing while sparing healthy tissues,” said Wayne Godfrey, M.D., Chief Medical Officer at Janux.
  • “We are grateful to our team and clinical investigators for their support in bringing another new therapeutic with a novel mechanism of action into the clinic.”

CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
Risk, Department, Gene, Population, Therapy, Vertex, Uncertainty, Survival, Regenerative medicine, Company, Form 10-K, CRISPR Therapeutics, CRSP, City of Hope, Acupuncture & Electro-Therapeutics Research, Toxic epidermal necrolysis, City, Knowledge, SEC, U.S. Securities and Exchange Commission, AML, Patient, Bayer, Private Securities Litigation Reform Act, H. Lee Moffitt Cancer Center & Research Institute, Nasdaq, Oncology, Hemoglobinopathy, Annual report, Cancer, FACP, Acute myeloid leukemia, CD83, Coronavirus, Gene editing, Toxicity, Clinical trial, Poster, Degenerative disease, GLOBE, Technology, CAR, RCC, Safety, CRISPR, Cas9, TGFBR2, Vaccine, Pharmaceutical industry

We are very pleased by the encouraging data from our first-in-human clinical trial exploring CD70-targeting CAR-T cell therapy in clear cell RCC.

Key Points: 
  • We are very pleased by the encouraging data from our first-in-human clinical trial exploring CD70-targeting CAR-T cell therapy in clear cell RCC.
  • Morrow, M.D., FACP, Chief Medical Officer of CRISPR Therapeutics.
  • At present, a treatment that offers patients with advanced kidney cancer the possibility of a durable remission with limited toxicity remains elusive.
  • CRISPR THERAPEUTICS word mark and design logo, COBALT, CTX130, and CTX131, are trademarks and registered trademarks of CRISPR Therapeutics AG.

Reducing Genetic Testing Barriers for the Charcot-Marie-Tooth Community

Retrieved on: 
Tuesday, August 9, 2022
Health, Genetics, Other Science, General Health, Research, Science, Biotechnology, CMT, Neurotoxicity, HNF, Genetic testing, Gene, Vitamin, Industry, Drug discovery, Mental health, Precision medicine, CEO, Diagnosis, Cedars-Sinai Medical Center, Research, Pain, Goldman Sachs, Occupational therapy, Peripheral neuropathy, Government, Human, Health, Patient, Quality of life, Sensation, Education, Partnership, Drug development, Awareness, Rock Health, Fenwick & West, Confusion, Acupuncture & Electro-Therapeutics Research, Genetics, Insurance, Hypoesthesia, Digital, Scene, Genetic counseling, LCGC, Charcot–Marie–Tooth disease, Medicine, Vaccine, Pharmaceutical industry

The CMT community has historically lacked education and resources around the importance and availability of genetic counseling, genetic testing, clinical trials and research participation.

Key Points: 
  • The CMT community has historically lacked education and resources around the importance and availability of genetic counseling, genetic testing, clinical trials and research participation.
  • These providers are often hesitant to pursue genetic testing, due to a perceived lack of approved treatments and discomfort surrounding test ordering and interpretation.
  • Through the CMT Genie Project, genetic counseling will be offered to participants at a reduced price, and the genetic counselor will help participants choose the most cost-effective genetic test that meets their needs.
  • For so long, theres been significant confusion around why and how to get genetic testing for CMT, says Allison Moore, founder and CEO, HNF.

Patient-Powered Registry Boosts the Study of Charcot-Marie-Tooth Disease and Collects Data for Clinician Observation

Retrieved on: 
Friday, September 3, 2021
Patient, IRB, CMT, Awareness, Government, Observation, Drug discovery, AI, Charcot–Marie–Tooth disease, Quality of life, Drug development, Peripheral neuropathy, HNF, Diagnosis, IPhone, Research, Industry, HIPAA, Goal, Acupuncture & Electro-Therapeutics Research, Gaps, Disease, Data collection, Pharmaceutical industry

HNF's Global Registry for Inherited Neuropathies (GRIN), an IRB-approved, online database collects genetic reports, and specific diagnostic and medical tests, as well as self-reported patient data through the use of surveys.

Key Points: 
  • HNF's Global Registry for Inherited Neuropathies (GRIN), an IRB-approved, online database collects genetic reports, and specific diagnostic and medical tests, as well as self-reported patient data through the use of surveys.
  • Additionally, visual documentation of challenges with activities of daily living, and expert assessment of the progression of the disease is collected.
  • Natural history studies are critical to understanding conditions such as Charcot-Marie-Tooth (CMT) and advancing research to discover and develop new therapies.
  • HNF identified several gaps in existing CMT natural history studies: the lack of collaboration amongst stakeholders, the lack of clinician observation of clinically relevant data, and the need to enroll more CMT patients.

20 years later, the Hereditary Neuropathy Foundation brings back its "eye-catching" PSA in support of Charcot-Marie-Tooth Awareness Month

Retrieved on: 
Wednesday, September 1, 2021
Industry, Nerve Damage, Friends, Quality of life, Muscle atrophy, Peripheral neuropathy, Gene, Charcot–Marie–Tooth disease, Public service, Diagnosis, Family, Social media, CMT, Research, Government, Drug discovery, PSA, Disease, HNF, Awareness, Injury, Acupuncture & Electro-Therapeutics Research, Multimedia, Bullying, Public service announcement, The, Motion, Chronic pain, Patient, Self-care, Atrophy, CEO, Movement, Physical education, Facebook, Muscle weakness, View, Drug development, Pharmaceutical industry, Nightclub, Online shopping

NEW YORK, Sept. 1, 2021 /PRNewswire/ -- The Hereditary Neuropathy Foundation (HNF), an advocacy and research non-profit 501(c)3 organization, today brings back its "eye-catching" Public Service Announcement (PSA) 20 years after it was initially launched.

Key Points: 
  • NEW YORK, Sept. 1, 2021 /PRNewswire/ -- The Hereditary Neuropathy Foundation (HNF), an advocacy and research non-profit 501(c)3 organization, today brings back its "eye-catching" Public Service Announcement (PSA) 20 years after it was initially launched.
  • Currently, thousands of people with CMT are undiagnosed, yet are suffering with the symptoms of this chronic and often disabling disease.
  • Children are often pushed into Physical Education class and other activities that are not adapted to their special needs.
  • Show your support for CMT families and increase awareness across the globe by updating your Facebook profile photo with your exclusive frame.